Yoko Yanagisawa

Evaluation of <i>PIK3CA</i> Mutation As a Predictor of Benefit From Nonsteroidal Anti-Inflammatory Drug Therapy in Colorectal Cancer

Enric Domingo, David N. Church, Oliver M. Sieber et al. · Journal of Clinical Oncology · 2013 · 210 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase III Randomized Trial Assessing Rofecoxib in the Adjuvant Setting of Colorectal Cancer: Final Results of the VICTOR Trial

Rachel Midgley, Christopher C. McConkey, Elaine Johnstone et al. · Journal of Clinical Oncology · 2010 · 99 citations · Full text

Medicine, Oncology, Pharmacology +15

Modified Irinotecan/5FU/Leucovorin therapy in advanced colorectal cancer and predicting therapeutic efficacy by expression of tumor-related enzymes

Yoko Yanagisawa, Fukuto Maruta, Nobuyoshi Iinuma et al. · Scandinavian Journal of Gastroenterology · 2006 · 31 citations

Medicine, Oncology, Pharmacology +17

Reduction of Calponin h1 expression in human colon cancer blood vessels

Yoko Yanagisawa, Michiko Takeoka, Takashi Ehara et al. · European Journal of Surgical Oncology · 2007 · 28 citations

Medicine, Cancer Biology, Oncology +10

Aberrant P53 expression lacks prognostic or predictive significance in colorectal cancer: results from the VICTOR trial.

Megan J McGregor, Wakkas Fadhil, Rose Wharton et al. · PubMed · 2015 · 11 citations

Medicine, Oncology, Pharmacology +17